Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sawai: Strong Sales to Pharmacies Boost Sales, Profits
November 29, 2010
- Eisai Enters into Research Collaboration with FORMA
November 29, 2010
- Sales, Profits Up for 3 Leading Dispensing Pharmacy Chains
November 29, 2010
- Taiyo: Profits Down Due to Business Suspension
November 29, 2010
- Sekisui Chemical Acquires Diagnostics Business from Genzyme
November 29, 2010
- 42 National Univ. Hospitals to Investigate Mutual Drug Purchase Prices
November 29, 2010
- Towa: Sales, Profits Outperform Forecasts
November 29, 2010
- Miraca HD: Acquisition Drives Sales, Up 9.9%
November 29, 2010
- Long-Listed Products May Undergo Additional 5% Price Cut in 2012: Mr Sakai of Credit Suisse
November 29, 2010
- Fuji Pharma: Record-High Sales, Profits Driven by Diagnostics
November 29, 2010
- Eiken: Sales Up 0.9% with Double-Digit Increases in Profits
November 29, 2010
- Rasilez Ranked No. 1 in HP Market: RepTrack Survey
November 29, 2010
- Nippon Chemiphar: Generics Push Up Sales, Profits
November 29, 2010
- Eisai Aims at US$1 Bil. Sales for Eribulin
November 29, 2010
- Kyorin: Sales Up 2.2% Driven by Kipres
November 22, 2010
- Price Settlement Rate 49.8% as of Sept. 30: CEO Kumakura of MEDIPAL
November 22, 2010
- Need for Economic Assessment of Drugs Pointed Out at Chuikyo
November 22, 2010
- Nippon Shinyaku: Cialis Drives Sales
November 22, 2010
- Alfresa: Operating Profits More than Double
November 22, 2010
- Afinitor Approved for Brain Tumors: Novartis
November 22, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…